

Figure S1. Uncropped Western blot images of the protein content of caspase-3, related to Figure 1C.





Figure S2. Uncropped Western blot images of the cytochrome levels c, caspase-3, caspase-9, and PARP, related to Figure 2A.





Figure S3. Uncropped Western blot images of the protein levels FasL, Fas, and caspase-8, related to Figure 2C.












Figure S4. (A) Uncropped Western blot images of the conversion of LC3-I to LC3-II, related to Figure 4A. (B) Uncropped Western blot images of protein levels in ATG4B. Densitometric analysis measured relative changes in protein bands with the control as 1.0-fold as shown just below the gel data, related to Figure 4E.

A**B**






Figure S5. (A) Uncropped Western blot images of the proteins Bax and Bcl-2. Relative changes in the Bax/Bcl-2 ratio have been measured using commercially available quantitative software with a control representing 1-fold, related to Figure 6A. (B) Uncropped Western blot images of the Beclin-1 and Bcl-2 proteins expression. Relative changes in the Beclin-1/Bcl-2 ratio were measured by commercially available quantitative software with a control as 1-fold, related to Figure 6B. (C) Uncropped Western blot images of the apoptotic proteins (caspase-3 and PARP) and autophagy markers (LC3-I/LC3-II and p62/SQSTM1), with co-treatment of 0, 1, 3, 6, 12, and 24 h after FKB (2.5 μ g/mL) and doxorubicin (0.5 μ g/mL), related to Figure 6C.


A




LC3-I/II
(16/14 KDa)




Procaspase-3
(35 KDa)
Caspase-3
(19/17 KDa)




β -actin
(43 KDa)




B




LC3-I/II
(16/14 KDa)




Procaspase-3
(35 KDa)
Caspase-3
(19/17 KDa)




β -actin
(43 KDa)




C



LC3-I/II
(16/14 KDa)



Procaspase-3
(35 KDa)
Caspase-3
(19/17 KDa)



β-actin
(43 KDa)






Figure S6. (A–B) Uncropped Western blot images of Inhibition of autophagy caused by FKB/doxorubicin suppressed apoptosis. Cells were pretreated with 3-MA (1 mM), related to Figure 7A–B. **(C)** Uncropped Western blot images of the monitored changes in the LC3-I/II and caspase-3 expressions, related to Figure 7C.


A




p-ERK1/2
(44/42 KDa)




ERK1/2
(44/42 KDa)



Procaspase-3
(35 KDa)
Caspase-3
(19/17 KDa)




PARP
(116 KDa)
Cleaved PARP
(89 KDa)



LC3-I/II
(16/14 KDa)



β-actin
(43 KDa)





B

Figure S7. (A–B) Uncropped Western blot images of The effect of FKB and doxorubicin co-treatment on expression of LC3-I/II, caspase-3, and PARP was investigated and then changes in total and phosphorylated levels of ERK and JNK were assessed by Western blot, with caspase-3 and PARP expressions, related to Figure 8A–B.




Figure S8. (A) Uncropped Western blot images of the terms caspase-3, PARP, and LC3-I/II, related to Figure 10A. (B-C) Uncropped Western blot images of The monitored for the terms ATG4B and p-ERK, related to Figure 10B-C.




Figure S9. (A) Uncropped Western blot images of the the expression caspase-3, caspase-8, caspase-9, and PARP related to Figure 11D. (B) Uncropped Western blot images of The changes in the expression of Bax and Bcl-2 proteins, related to Figure 11E.